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ATPase, also alter the function of the renal tubular epithelialMechanism of FK 506/520 action on rat renal proximal tubular
cell.Na1,K1-ATPase activity.
Background. The neurotransmitter in renal sympathetic
nerves, norepinephrine (NE), regulates the activity of proximal
tubule (PT) Na1,K1-ATPase in a bidirectional manner via stimu- Treatment with FK 506 and cyclosporine is associatedlation of a- and b-adrenoceptors. The stimulatory a-adrenergic
with widespread activation of sympathetic nerves [1, 2].pathway is mediated by calcineurin, the target molecule for
The major sympathetic neurotransmitter norepinephrineFK 506 and related compounds. We examined whether the FK
506 analogue FK 520, by interrupting the calcineurin-mediated (NE) stimulates both a- and b-adrenoceptors. a-Adreno-
a-adrenergic signaling pathway, enhance the inhibitory b-adren- ceptors signal via different pathways, including acti-
ergic effect of NE on PT Na1,K1-ATPase activity. vation of the Ca21-dependent protein phosphatase 2B,
Methods. The effects of three days of treatment with FK
calcineurin, which is inhibited by both FK 506 and520 were examined on rat renal PT Na1,K1-ATPase activity,
cyclosporine [3–5]. Because calcineurin is the target mol-measured as ouabain-sensitive ATP hydrolysis in single, mi-
ecule for these agents, it is likely that FK 506 andcrodissected PT segments. Renal function studies, including
glomerular filtration rate (GFR) and urinary excretion of cyclosporine treatment will interrupt the a-adrenergic
N-acetyl-3-d-glucoseaminidase (NAG), were examined using signaling pathway.
conventional clearance techniques after three days of treat- Some cell types, including renal proximal tubular (PT)ment with FK 506.
cells, express both a- and b-adrenoceptors [6, 7]. Stimula-Results. FK 520 treatment induced a pronounced and dose-
tion of these two receptor subtypes often has oppositedependent decrease in PT Na1,K1-ATPase activity. This effect
was completely reversed by the competitive FK 520 antagonist, biological effects. An example of this is the regulation
L 685 818, indicating that the effect was dependent on inhibition of PT Na1,K1-ATPase activity. Stimulation of a-adreno-
of calcineurin. To test whether the FK 520-induced decrease ceptors increases Na1,K1-ATPase activity via calcineu-
in Na1,K1-ATPase activity was mediated by enhanced b-adre-
rin, whereas stimulation of b-adrenoceptors decreasesnoceptor signaling, the FK 520 effect was examined in rats
it. In a recent in vitro study, we showed that the dualpretreated with a b-adrenoceptor antagonist (propranolol) or
activation of a- and b-adrenoceptors resulted in no netrats subjected to renal denervation. Both of these procedures
prevented the FK 520-induced decrease in Na1,K1-ATPase effect of NE on PT Na1,K1-ATPase activity [8]. The
activity. Thus, during FK 520 treatment, renal sympathetic aim of this study was to examine whether an interruption
nerves mediate an inhibitory effect on PT Na1,K1-ATPase of the a-adrenergic pathway in vivo may result in en-
activity via b-adrenoceptors. Propranolol pretreatment also
hanced signaling via the b-adrenergic pathway. For thisprevented FK 506-induced decreases in GFR and urinary ex-
purpose, rats were treated with an FK 506 analogue,cretion of NAG, an index of PT dysfunction.
Conclusions. The results support the hypothesis that the net FK 520. The results showed that interruption of the
effect of the neurotransmitter NE on Na1,K1-ATPase activity a-adrenergic signaling pathway caused an inhibition of
is dependent on the balance between the a- and b-adrenergic PT Na,K-ATPase activity, mediated via b-adrenocep-
signaling pathways and suggest that agents that interfere with tors.these pathways may, by altering the activity of tubular Na1,K1-
Treatment with FK 506 and cyclosporine is associated
with impaired renal function. One component of this
nephrotoxicity is renal tubular dysfunction, whereas an-Key words: calcineurin, adrenergic nerves, renal Na1,K1-ATPase,
b-adrenoceptor antagonist, cell signaling, epithelial cell. other is decreased glomerular filtration rate (GFR) [9–12].
This effect is mediated by renal sympathetic nervesReceived for publication December 17, 1998
[2, 13, 14] and is linked to an inhibition of calcineurinand in revised form March 18, 1999
Accepted for publication April 1, 1999 [14]. Our findings therefore prompted us to examine
whether inhibition of the b-adrenergic pathway via treat- 1999 by the International Society of Nephrology
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ment with b-adrenoceptor antagonists ameliorated the afferent sensory neurotransmitter CGRP for at least one
week after the denervation [16, 17]. Three days afternephrotoxic effects of FK 506.
denervation, the animals in group 8 were treated with
the vehicle. Those in group 9 received FK 520 (40 mg/
METHODS
kg/day) for three days.
Animals In order to provoke nephrotoxicity, rats were treated
with parenterally administered FK 506 (1 mg/kg/day).Male Sprague-Dawley rats (B & K Universal, Sollen-
tuna, Sweden) aged 40 to 45 days and weighing between Group 1 received FK 506 (1 mg/kg/day) intramuscularly
for three days. Group 2 received the vehicle alone.150 and 200 g were used. They were fed ad libitum with
standard rat chow (Beaky, Fixed Formula; N. Humber- Group 3 received FK 506 (1 mg/kg/day) intramuscularly
in combination with propanolol (0.25 mg/kg/day) intra-side, Bantin & Kingman Ltd., UK) and had free access
to tap water. peritoneally for three days and, group 4 received pro-
pranolol alone (0.25 mg/kg/day intraperitoneally) forRats were treated for three days with two different
FK analogues, FK 506 and FK 520. FK 520 differs from three days. Treatment with propranolol was started 12
hours prior to FK 506 treatment and was administeredFK 506 by only one carbon atom and is an agonist of
the immunosuppressive activities of FK 506 [14]. This every 12 hours.
All in vivo studies were performed at day 4.FK agonist possesses approximately 50% of the activity
of FK 506 with regard to calcineurin inhibition [14]. In No significant changes in weight, food intake, or be-
havior were observed between the different groups.the physiological studies on PT Na1,K1-ATPase, rats
were treated with FK 520 because we wanted to avoid
Preparation of proximal tubule segmentsa drug that may also have toxic effects. In the studies
on renal function, including GFR, urinary N-acetyl-3- Kidney perfusion and tubule microdissection were
performed as described [18]. The rats were anesthetizedd-glucoseaminidase (NAG) and sodium excretion, and
blood pressure, rats were treated with the more potent with an intraperitoneal injection of Mebumal vet (5 to
6 mg per 100 g body wt; Nord Vacc, Stockholm, Sweden).FK analogue, FK 506. The tissue bioavailability of FK
506 after enteral administration is quite variable and Following a midline incision, the left kidney was exposed
and perfused with a cold, modified Hanks’ solution con-generally low [15]. The bioavailability of propranolol is
also improved after parenteral administration. To ex- taining 0.05% collagenase (Sigma Chemical Co., St.
Louis, MO, USA) and 0.1% bovine serum albuminclude the possibility that the observed beneficial effects
of b-adrenoceptor treatment were due to altered bio- (BSA; Behringwerke, Marburg, Germany). The pH was
adjusted to 7.4. The kidney was removed and cut alongavailability, both FK 506 and propranolol were adminis-
tered parenterally. Accordingly, the dosages of the two its corticopapillary axis into small pyramids that were
incubated for 20 minutes at 358C in the perfusion solutiondrugs were reduced.
In the studies on PT Na1,K1-ATPase, rats were containing 1023 m butyrate to optimize mitochondrial
respiration [19]. The solution was continuously bubbledtreated for three days with FK 520 (L 683 590) adminis-
tered via gavage (0.5 ml). FK 520 was dissolved in a with oxygen. After incubation, the tissue was rinsed with
fresh microdissection solution, which had the same com-vehicle of alcohol 1%, Tween 80 10%, and citrate buffer.
The rats were divided into nine groups. Group 1 received position as the perfusion solution, except that the CaCl2
concentration was 0.25 mm and collagenase and BSAonly the vehicle. Group 2 received 10 mg/kg/day of FK
520. Group 3 received 40 mg/kg/day of FK 520. Group were omitted.
The single PT segments were manually dissected (tu-4 received vehicle and 0.25 ml saline. Group 5 received 25
mg/kg/day of a nonselective b-adrenoceptor antagonist, bular segment length 0.4 to 1.1 mm) from the outer
cortex under a stereomicroscope at 48C. The tubule seg-propranolol, dissolved in 0.25 ml saline via gavage
(b-adrenoceptor antagonist treatment was started 12 hr ments were individually transferred to the concavity of
a bacteriological slide in a drop of the microdissectionbefore FK treatment and was given every 12 hr). Group
6 received FK 520 (40 mg/kg/day) and saline. Group 7 solution and photographed for length determination us-
ing an inverted microscope at a magnification of 3100.received FK 520 (40 mg/kg/day) plus propranolol (25 mg/
kg/day), and groups 8 and 9 were unilaterally denervated. The activity of Na1,K1-ATPase was related to the tubu-
lar length. Tubules were stored on ice until dissectionUnder light anesthesia, the left renal artery was dissected
free from surrounding tissue and was wrapped three was completed for a maximum of 30 to 60 minutes.
times for five minutes with cotton soaked in a solution
Preincubation of tubules with different drugsof 10% phenol in absolute alcohol [16]. The efficiency
of the denervation has been verified by immunofluores- In the in vitro study, the tubule segments were incu-
bated for 30 minutes at room temperature, either in 1cence studies that show the complete absence of the
efferent cotransmitter neuropeptide Y (NPY) and the ml of microdissection solution alone (control tubules) or
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The 32P-phosphate liberated by hydrolysis of ATP was
separated by filtration through a Millipore filter after
absorption of the unhydrolyzed nucleotide on activated
charcoal, and radioactivity was counted in a liquid scintil-
lation spectrometer.
In each study, total ATPase activity and ouabain-
insensitive ATPase activity were measured on each of
five to eight other tubule segments. Na1,K1-ATPase ac-
tivity (pmol of 32Pi hydrolyzed per mm of tubule length
per hour) was calculated as the difference between the
mean value for total ATPase and ouabain-insensitive
ATPase activity, and was expressed as an absolute value.Fig. 1. Effects of a-adrenoceptor agonists and FK 520 on the Na1,K1-
ATPase activity of single proximal tubule segments. Assays were per- Vehicle- and agent-treated rats, as well as control and
formed with a nonsaturating Na1 concentration of 20 mm. Values are experimental tubules, were always run in parallel.means 6 sem and are expressed as pmol Pi mm tubule21 · hr21 (N 5
3 to 6 per group). *P , 0.05 vs. control; **P , 0.05 vs. oxymetazoline,
Determination of renal functionNS 5 not significant vs. oxymetazoline, P , 0.05 vs. oxymetazoline and
FK 520 1027 m. Statistical analyses were performed with paired as well The renal function studies, performed during euvo-as unpaired Student’s t-tests.
lemic condition, were carried out as described [20]. To
determine the GFR, a 5% solution of Inutest (Laevosan,
Gesellschaft, Linz, Austria) diluted in Ringer’s solution
was infused via a constant infusion pump in a dose ofin 1 ml of microdissection solution containing oxymetazo-
line 1026 m 6 FK 520 1028 to 1025 m. In some experiments, 1% of body wt/hr. This infusion rate maintains the hema-
L 685 818 1024 m was added (experimental tubules). The tocrit stable during the experiment. The infusion was
sodium concentration of the microdissection solution preceded by a bolus dose of 1% body wt. Following an
was 20 mm in the in vitro study. The osmolality was equilibration period of one hour, urine collection was
kept constant by adding choline chloride. The specific started. The mean value from two consecutive 20-minute
conditions for each experiment are stated in Figure 1. periods of timed urine collection was used for further
In the in vivo study, the tubules from vehicle-treated calculations.
and agent-treated rats were incubated for 30 minutes at Sodium concentration was determined by flame pho-
room temperature in 1 ml of microdissection solution tometry.
without agents added, except for the study of reversibility Mean arterial pressure (MAP) was monitored with a
with L 685 818. Statham transducer and recorded on a polygraph (Model
7B, Grass Instrument, Quincy, MA, USA).
Determination of Na1,K1-ATPase activity The urinary NAG concentration was measured as de-
The preincubation period was stopped by cooling the scribed [21]. Briefly, 300 ml 0.05% p-nitrophenyl-N-ace-
tubular segments to 48C. The segments were made per- tyl-b-N-glucoseaminidine in 0.1 m citrate buffer, pH 4.5,
meable by repeated freezing and thawing. This proce- was incubated with 100 ml urine for 30 minutes at 378C.
dure allowed ATP and sodium-free access to the interior The reaction was terminated by the addition of 750 ml 0.2
of the cell. The tubules were incubated at 378C for 15 m borate-buffer, pH 9.8. The generation of p-nitrophenol
minutes in a medium containing (in mm): 70 NaCl (20 was measured at 408 nm by a spectrophotometer (LKB
NaCl), 5 KCl, 10 MgCl2, 1 EGTA, 100 Tris-HCl, 10 Tris- 7400). The values are expressed as the ratio between
ATP, and g-[32P] ATP (NEN, Boston, MA, USA), as urinary NAG concentration and GFR.
well as 2 to 5 Ci mmol21 in trace amounts (5 nCi ml21).
Statistical analysisBy adding ATP in excess, cytotoxic-induced depletion
of ATP was abolished as a primary cause of alterations Values are given as mean 6 sem. One-way analysis of
in Na1,K1-ATPase activity. Oxymetazoline increases variance (Dunnett’s method) and unpaired Student’s
Na1,K1-ATPase activity under conditions of nonlimiting t-test were used to compare vehicle and drug-treated
Na concentrations (20 mm). The effect of FK 520 on animals. Paired and unpaired Student’s t-tests were used
oxymetazoline-induced increase in Na1,K1-ATPase was to compare control and experimental tubules. A value
therefore examined at 20 mm Na1. When the Na1 con- of P , 0.05 was considered significant.
centration was varied, choline chloride was added to
keep osmolality constant at 290 mOsm/kg of H2O. For
RESULTSdetermination of ouabain-insensitive ATPase activity, 2
We have previously reported that the nonselectivemm ouabain (USB, Cleveland, OH, USA) was added.
NaCl and KCl were omitted, and Tris-HCl was 150 mm. a-adrenoceptor agonist oxymetazoline dose dependently
Holtba¨ck and Eklo¨f: FK506/520 effects on Na1,K1-ATPase 1017
Table 1. Effects of a-adrenoceptor agonist and FK 506 analogs on
proximal tubular (PT) Na1, K1-ATPase activity
Na1, K1-ATPase activity
Addendum pmol Pi mm21·h21 N
— 1626683 5
Oxymetazoline 2386695a 7
Oxymetazone and FK 520 1602 6104b 7
Oxymetazoline, FK 520 and
L 685 818 2392 1162c 5
FK 520 17581111 NS 5
L 685 818 1755 172 NS 5
Quantities are: oxymetazoline 1026 m, FK 520 1026 m, L 685 818 1024 m. NS
is not significant versus control.
a P , 0.05 vs. control
b P , 0.05 vs. oxymetazoline
Fig. 2. The inhibitory effect on proximal tubule (PT) Na1,K1-ATPasec P , 0.05 vs. oxymetazoline and FK 520
activity after three days of treatment with FK 520 was reversed by the
FK antagonist. FK 520 was administered via gavage at a dosage of 40
mg/kg/day. Microdissected PT segments were incubated with L685 818
1024 m for 30 minutes. Assays were performed in the presence of 70
mm Na1. Values are means 6 sem and are expressed as pmol Pi mmincreases Na1,K1-ATPase activity and that this effect is
tubule21 · hr21 (N 5 4 to 5 per group). *P , 0.05 vs. control; **P ,abolished by FK 506 [22, 23]. Here we examined whether 0.05 vs. FK 520 and not significant vs. control (P , 0.1). NS 5 not
the FK 506 analogue FK 520 was able to block a-ad- significant vs. control. Statistical analyses were performed with unpaired
Student’s t-test.renoceptor agonist-induced increases in PT Na1,K1-
ATPase activity. The effect was evaluated with regard
to dose–response effects and specificity in in vitro studies.
Oxymetazoline-induced increases in PT Na1,K1-
ATPase activity were inhibited by FK 520 (Fig. 1), and
a significant effect of FK 520 was observed at 1027 m. FK
520 1026 m completely abolished the stimulatory effect of
oxymetazoline on Na1,K1-ATPase activity. To examine
the specificity of the response, a competitive antagonist
to FK 506, L 685 818, was used [14]. L 685 818 (1024 m)
completely reversed the inhibitory effect of FK 520 (1026
m) on oxymetazoline-induced increases in Na1,K1-
ATPase activity (Table 1). In the absence of oxymetazo-
line, neither FK 520 nor L 685 818 had any effect on the
Na1,K1-ATPase activity (Table 1).
Fig. 3. Effect of b-adrenoceptor antagonist treatment on FK 520-Treatment for three days with FK 520 significantly induced decrease in proximal tubule (PT) Na1,K1-ATPase activity. FK
decreased PT Na1,K1-ATPase activity in a dose-depen- 520 and propranolol were administered via gavage at a dosage of 40
and 25 mg/kg/day, respectively. Assays were performed in the presencedent manner. Two different doses of FK 520 were given:
of 70 mm Na1. Values are means 6 sem and are expressed as pmol Pi
10 mg/kg/day, which would correspond to the pharmaco- mm tubule21 · hr21. N 5 5 per group. *P , 0.05 vs. control. **P , 0.05
vs. FK 520 and not significant vs. control. Statistical analyses werelogical dose of FK 506 in rats (6 mg/kg/day), and 40 mg/
performed with unpaired Student’s t-test.kg/day. The control value of 2496 6 120 (N 5 9) was
reduced to 1834 6 216 by FK 520 at 10 mg/kg/day (N 5
3, P , 0.05 vs. control) and to 1464 6 172 by FK 520 at
40 mg/kg/day (N 5 9, P , 0.05 vs. control, P , 0.05 vs. ity via activation of calcineurin [22], whereas stimulation
FK 520 at 10 mg/kg; units are pmol Pi mm tubule21 · of b-adrenoceptors decreases Na1,K1-ATPase activity
hr21). To evaluate the specificity and the mechanisms of [8]. Because the a-adrenergic signaling pathway is inter-
the in vivo effects of FK 520, a dose of 40 mg/kg/day rupted by FK 520, we speculated that the decrease in
was used in the following protocols. The decrease in Na1,K1-ATPase activity during FK 520 treatment was
Na1,K1-ATPase activity following three days of treat- achieved by unopposed stimulation of the b-adrenergic
ment with FK 520 was reversed by a 30-minute incuba- signaling pathway. To examine this hypothesis, rats were
tion of single PT segments with L 685 818 (1024 m; Fig. treated for three days with a nonselective b-adren-
2). In vehicle-treated rats, the FK antagonist had no oceptor antagonist, propranolol (25 mg/kg/day), together
effect on Na1,K1-ATPase activity. with FK 520. The inhibitory effect of FK 520 on Na1,K1-
The PT cell expresses both a- and b-adrenoceptors ATPase activity was significantly reversed by b-adren-
[6, 7]. In previous studies, we have shown that stimulation oceptor antagonist treatment (Fig. 3).
Treatment with propranolol in the absence of FK 520of a-adrenoceptors increases the Na1,K1-ATPase activ-
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Fig. 4. Effect of renal denervation on FK 520 induced decrease in
proximal tubule (PT) Na1,K1-ATPase activity. FK 520 was adminis-
tered via gavage at a dosage of 40 mg/kg/day. Assays were performed Fig. 5. Effect of FK 506 and b-adrenoceptor antagonist treatment on
in the presence of 70 mm Na1. Values are means 6 sem and are expressed urinary excretion of NAG. FK 506 was administered intramuscularly
as pmol Pi mm tubule21 · hr21. Innervated N 5 4 per group, denervated at a dosage of 1 mg/kg, and propranolol was administered intraperitone-
N 5 6 per group. *P , 0.05 vs. control in innervated. NS is not significant ally at a dosage of 0.25 mg/kg/day. Values are means 6 sem and are
vs. control in denervated group. Statistical analyses were performed expressed as pcat/min (N 5 8 per group). *P , 0.05 vs. control;
with unpaired Student’s t-test. **P , 0.05 vs. FK 506 alone and not significant vs. control. Statistical
analyses were performed with unpaired Student’s t-test as well as one-
way analysis of variance (Dunnett’s method).
had no effect on Na1,K1-ATPase activity [control (N 5
4), 2776 6 460; propranolol (N 5 4), 2734 6 122 pmol
Pi mm tubule21 · hr21].
In the next protocol, the effect of three days of treat-
ment with FK 520 was examined in rats that had under-
gone unilateral renal denervation seven days previously.
Chemical denervation of renal sympathetic nerves sig-
nificantly reduced the inhibitory effect of FK 520 treat-
ment on Na1,K1-ATPase activity (Fig. 4). FK 520 de-
creased the Na1,K1-ATPase activity in the innervated
kidneys by 48 6 3% but only by 20 6 2% in the dener-
vated kidneys (P , 0.05). Calcineurin has a key position
in the stimulatory pathway of PT Na1,K1-ATPase. Not
only a-adrenoceptors but also angiotensin II, C-peptide,
and NPY increase Na1,K1-ATPase activity via cal-
Fig. 6. Effect of FK 506 and b-adrenoceptor antagonist treatment oncineurin [23–25]. The residual decrease in Na1,K1-
glomerular filtration rate (GFR). FK 506 was administered intramuscu-ATPase activity after renal denervation may indicate larly at a dosage of 1 mg/kg, and propranolol was administered intraperi-
that the stimulatory effect of these factors is diminished toneally at a dosage of 0.25 mg/kg/day. Values are means 6 sem and
are expressed as ml/min (N 5 8 per group) *P , 0.05 vs. control;during FK 520 treatment.
**P , 0.05 vs. FK 506 alone and not significant vs. control. StatisticalFK 506-induced nephrotoxicity includes metabolic alter- analyses were performed with unpaired Student’s t-test as well as one-
ations in the PT epithelial cells and decreased GFR [9, 10]. way analyses of variance (Dunnett’s method).
To examine whether propranolol treatment would pro-
tect from the clinical signs of FK 506-induced nephrotox-
icity, we conducted an in vivo study in which rats were
After three days of treatment with FK 506 and/ortreated with FK 506, an FK analogue known to induce
propranolol, no significant alterations in MAP weresignificant nephrotoxic effects [9, 10, 14]. FK 506 was
noted between the different groups.injected intramuscularly at a dose of 1 mg/kg/day for
Treatment with FK 506 decreased urinary sodium ex-three days. This treatment significantly increased urinary
cretion [control (N 5 8), 0.14 6 0.04; FK 506 (N 5 8),NAG excretion and decreased GFR. When FK 506 treat-
0.04 6 0.03 mmol/min]. This antinatriuretic response isment was combined with propranolol, both of these renal
most likely due to increased sodium reabsorption ineffects were abolished (Figs. 5 and 6). Treatment with
more distal nephron segments, where the finely-tunedpropranolol alone had no effect on NAG excretion [NAG
control of sodium balance occurs. Ciresi et al demon-control (N 5 8), 1.28 6 0.20; propranolol (N 5 8), 0.94 6
strated a natriuretic response during the first days of0.11 pcat/min] or GFR [GFR control (N 5 8), 2.33 6
0.10; propranolol (N 5 8), 2.54 6 0.20 ml/min]. cyclosporine treatment [25]. After three days of treat-
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Fig. 7. Schematic model of a-adrenergic and
b-adrenergic signaling pathways in rat proxi-
mal tubular (PT) epithelial cells. The renal
neurotransmitter norepinephrine stimulates
a- and b-adrenoceptors, with opposing effects
on PT Na1,K1-ATPase activity. FK 506 treat-
ment activates renal sympathetic nerves and
inhibits the phosphatase activity of calcineurin.
The FK 506 analogue FK 520 interrupts the
a-adrenergic signaling pathway. Therefore,
during treatment with FK 520, norepinephrine
(NE) signals predominantly via b-adrenocep-
tors, and a decrease in PT Na1,K1-ATPase
activity occurs.
ment, sodium balance became progressively positive; this activity of renal sympathetic nerves [1]. Several tissues,
including renal PT cells, express a- and b-adrenoceptors,was associated with activation of the renin-angiotensin-
aldosterone system and suppression of circulating atrial which can exert opposing effects on target molecules.
The net effect of NE, the main neurotransmitter [29, 30],natriuretic peptide concentration [26]. Renin release is
mediated, in part, by activation of renal sympathetic on the target molecule may therefore depend on the
balance between the a- and b-adrenergic signaling path-nerves, which is blocked by b-adrenoceptor antagonists
[27, 28]. In our study, we found that in control rats, treat- way. NE regulates PT Na1,K1-ATPase activity via both
a- and b-adrenoceptors via several signaling pathwaysment with propranolol induced a natriuretic response
(Fig. 7). NE, acting on a-adrenoceptors, increases[control (N 5 8), 0.14 6 0.04; propranolol (N 5 6), 0.57 6
Na1,K1-ATPase activity through activation of calcineu-0.08 mmol/min], whereas the antinatriuretic response to
rin. Stimulation of b-adrenoceptors decreases Na1,K1-FK 506-treatment was unchanged by propranolol treat-
ATPase activity. As a result of this dual stimulation ofment [FK 506 (N 5 8), 0.04 6 0.03; FK 506 1 propranolol
a- and b-adrenoceptors, NE may have no consistent net(N 5 8), 0.05 6 0.02 mmol/min]. This finding indicates
effect on PT Na1,K1-ATPase activity [8]. FK 506 actsthat b-adrenoceptor activation is not involved in the
by inhibiting calcineurin, a Ca21-dependent proteinantinatriuretic response to FK 506 treatment.
phosphatase involved in intracellular signaling in various
tissues [3–5]. In this study, we found that the FK 506
DISCUSSION analogue FK 520 abolished a-adrenoceptor agonist-
Norepinephrine is generally considered to increase re- induced increases in Na1,K1-ATPase activity, an effect
nal PT Na1,K1-ATPase activity via stimulation of a-adre- that was linked to an inhibition of calcineurin. Three
noceptors [22, 23]. In a recent study, we found that the days of treatment with FK 520 induced a dose-dependent
net effect of NE on PT Na1,K1-ATPase was not consis- decrease in PT Na1,K1-ATPase activity. This effect was
tent. NE increased Na1,K1-ATPase activity only in the mediated by renal sympathetic nerves acting via b-adre-
presence of b-adrenoceptor antagonists and decreased noceptors because renal denervation as well as treatment
it in the presence of a-adrenoceptor antagonists. Neuro- with the b-adrenoceptor antagonist propranolol pre-
peptide Y, a cotransmitter with NE in sympathetic nerve vented the FK 520-induced decrease in Na1,K1-ATPase
endings, shifted the equilibrium between a- and b-adre- activity. Taken together, these results indicate that FK
nergic tonus toward a stimulatory effect of NE on PT 520 treatment can shift the balance of the effect of NE
Na1,K1-ATPase activity [8]. In this study, we found that on Na1,K1-ATPase activity toward the inhibitory b-adre-
interruption of the a-adrenergic signaling pathway nergic pathway by interrupting the calcineurin-mediated,
shifted the action of NE on Na1,K1-ATPase toward an stimulatory a-adrenergic pathway.
inhibition. When the a-adrenergic signaling pathway was Proximal tubular cell damage is one component of FK
blocked, NE could only signal via the b-adrenergic path- 506-induced nephrotoxicity. This effect is characterized
way, and consequently, a decrease in Na1,K1-ATPase by impaired tubular epithelial cell function, cell swelling
occurred. This finding is of potential clinical interest as progressive histological changes, and finally, cell death
a-adrenergic stimulation of PT Na1,K1-ATPase is medi- and tubular collapse [9, 10]. Na1,K1-ATPase is responsi-
ated via protein phosphatase 2B (calcineurin), which is ble for cellular sodium efflux and thereby has a profound
the target for the immunosuppressive drugs FK 506 and influence on cell volume and cell metabolism [31–34]. It is
cyclosporine. possible that the effect of FK 520 treatment on Na1,K1-
ATPase activity contributes to its toxic effects. The uri-Treatment with FK 506 is associated with increased
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potassium-adenosine triphosphatase; NE, norepinephrine; PT, proxi-nary excretion of NAG is considered to be an index of
mal tubule.
early PT cell injury. The FK 506-induced increase in uri-
nary NAG excretion was normalized when PT Na1,K1-
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